DocMorris AG Charts Costly Yet Credible Turnaround

DocMorris AG ((CH:DOCM)) has held its Q4 earnings call. Read on for the main highlights of the call.

DocMorris AG’s latest earnings call painted a cautiously optimistic picture, with strong revenue and digital growth offsetting heavy current losses. Management emphasized improving margins, tight cost control, and a solid liquidity buffer, arguing that operational momentum and a clear route to profitability outweigh today’s financial and logistical headwinds.

Revenue Growth

Group revenue rose 11.1% in FY2025 in local currency, underlining solid demand despite market challenges. Excluding the Apotal divestment, reported revenue growth accelerated to 12.4%, showing that the core platform is expanding at a healthy double‑digit pace.

Strong Rx and Digital Services Momentum

Prescription (Rx) revenue surged about 33% year over year, while non‑Rx sales grew 7.1%, confirming broad‑based growth. Digital Services were the standout, with revenues jumping 110% and already making a strong contribution to group profitability.

Digital Services Profitability and TeleClinic Scale

TeleClinic delivered around 2 million treatments in 2025, growing more than 50% and generating EUR 26 million in take‑rate revenue. Together with Retail Media, these high‑margin digital activities now contribute the majority of CM3, making them key profit engines.

Platform Reach and Customer Metrics

DocMorris’ online pharmacy platform now serves roughly 11 million active customers, an increase of about 700,000 over the year. TeleClinic’s customer base climbed from 0.9 million to 1.2 million, while app downloads rose to 2.1 million, indicating strengthening ecosystem reach.

Higher Average Order Value and Retention Improvements

The average Rx order value increased, with Q4 electronic prescription baskets reaching about EUR 128 and roughly EUR 4 higher than a year earlier. Customer order frequency ticked up from 3.9 to 4.0 orders per year and repeat order rates improved from 76% to 77%, supporting lifetime value.

Gross Margin and Cost Efficiency Improvements

Group gross margin expanded by roughly 90 basis points to 22.2%, even after shifting some marketing into bonuses and co‑payments booked as sales deductions. Personnel costs were trimmed relative to revenue, with the ratio improving by about 50 basis points as early efficiency measures take hold.

Balance Sheet and Liquidity Strength

Year‑end liquidity stood at CHF 160 million, giving the company a comfortable cash cushion for its transition phase. Net debt was reduced to CHF 138 million and the equity ratio improved to around 50%, with a remaining 2026 convertible already redeemed in March.

Clear Path to Profitability

Management laid out a roadmap to reach EBITDA breakeven during 2026, helped by scaling high‑margin digital services and a stronger CM3. Free‑cash‑flow breakeven is targeted for 2027, signaling a shift from growth‑funded losses to a more self‑financing model within two years.

AI Health Companion Adoption and Clinical Impact

The AI Health Companion, launched in beta in October 2025, is already used by about one in three app users, pointing to rapid uptake. Its skin‑check service has enabled early detection of over 200 skin tumors and melanomas in just two months, strengthening DocMorris’ clinical relevance.

Strategic Partnership with Google

DocMorris announced a strategic collaboration with Google to tap advanced AI capabilities while keeping full control over data privacy. Management expects the partnership to accelerate product development, deepen user engagement, and lift overall platform value.

Retail Media Growth

Retail Media, launched roughly three years ago, now generates double‑digit million euro revenues and carries very high margins. Positioned as a leading health‑care retail media platform in Germany, it is reported to be even more profitable than TeleClinic.

Large Adjusted EBITDA Loss in FY2025

Despite operational progress, FY2025 adjusted EBITDA was deeply negative at around CHF ‑48.2 million, underscoring the size of the turnaround task. Management stressed that narrowing these losses in 2026 is a top priority as the business scales.

Distribution and Logistics Cost Pressure

Distribution expenses rose as logistics and transport costs climbed sharply, weighing on profitability. Management signaled that some of these pressures may eventually be passed through to customers or addressed via changes in delivery models.

Higher Marketing Spend and Reallocation Effects

Direct marketing spending increased by more than CHF 11 million in 2025 as DocMorris invested to drive growth and retention. Part of the marketing budget was reallocated into bonuses and co‑payments that reduce reported gross margin but improve customer loyalty and long‑term value.

Segment EU Underperformance

The EU segment delivered only modest revenue growth and remained slightly EBITDA negative, despite a roughly 40 basis‑point gross margin improvement. Low top‑line momentum combined with a largely fixed indirect cost base kept the segment from contributing meaningfully to earnings.

Non‑Cash Financial and Tax Charges

The net financial result deteriorated by about CHF 12 million year on year, mainly due to non‑cash foreign exchange effects and bond repurchase costs. Additionally, a CHF 12 million deferred tax charge tied to deferred tax asset valuation weighed on reported profit, though it did not affect cash flow.

Working Capital and Receivables Issues

Net working capital was hurt by around CHF 11 million of overstocking, with management admitting roughly CHF 5 million could have been avoided. Accounts receivable issues of CHF 9 million were described internally as sloppiness to be fixed, pointing to operational tightening ahead.

One‑Off Restructuring Costs from Site Closure

Closing the Ludwigshafen site will trigger one‑off restructuring costs of EUR 3–4 million and reduce EBITDA by about EUR 2 million in the near term. From 2027 onward, the move is expected to generate recurring annual savings of more than EUR 2 million, enhancing structural efficiency.

Guidance Uncertainty Driven by Rx Volatility

For 2026, revenue guidance spans from mid‑single‑digit to low‑teens growth, with Rx volatility identified as the main swing factor. Management aims to keep flexibility to prioritize either faster growth or higher profitability as market conditions evolve.

Refinancing and Liquidity Risk Over Time

While current liquidity is solid, DocMorris expects another year of negative free cash flow in 2026 and faces a convertible maturity in 2028. Management acknowledged that refinancing options will need to be addressed in due course but ruled out a near‑term sale of TeleClinic as a funding measure.

Forward‑Looking Guidance

Looking ahead, DocMorris targets 2026 revenue growth in a broad mid‑single‑digit to low‑teens range, with Rx around 20%, OTC/BPC mid‑single‑digit, and Digital Services mid‑double‑digit. EBITDA is guided to CHF ‑10 to ‑25 million with breakeven during 2026, CM3 margin up about 300 basis points, CapEx near CHF 30 million, free‑cash‑flow breakeven in 2027, and midterm revenue CAGR of about 15% to 2030.

DocMorris’ earnings call portrayed a business balancing rapid digital expansion with the hard work of restoring profitability and tightening operations. For investors, the story hinges on management delivering on its 2026–2027 breakeven roadmap while managing cost inflation and refinancing, but the growth in Rx, digital services, and AI‑driven tools offers a compelling upside narrative.